These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 22819849)

  • 21. Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.
    Brnjic S; Mazurkiewicz M; Fryknäs M; Sun C; Zhang X; Larsson R; D'Arcy P; Linder S
    Antioxid Redox Signal; 2014 Dec; 21(17):2271-85. PubMed ID: 24011031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells.
    Ding W; Wang JX; Wu JZ; Liu AC; Jiang LL; Zhang HC; Meng Y; Liu BY; Peng GJ; Lou EZ; Mao Q; Zhou H; Tang DL; Chen X; Liu JB; Shi XP
    Acta Pharmacol Sin; 2023 Dec; 44(12):2537-2548. PubMed ID: 37528233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
    Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
    Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.
    Liu N; Li X; Huang H; Zhao C; Liao S; Yang C; Liu S; Song W; Lu X; Lan X; Chen X; Yi S; Xu L; Jiang L; Zhao C; Dong X; Zhou P; Li S; Wang S; Shi X; Dou PQ; Wang X; Liu J
    Oncotarget; 2014 Jul; 5(14):5453-71. PubMed ID: 24977961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
    Zhang X; Selvaraju K; Saei AA; D'Arcy P; Zubarev RA; Arnér ES; Linder S
    Biochimie; 2019 Jul; 162():46-54. PubMed ID: 30946948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
    Landis-Piwowar KR
    Clin Lab Sci; 2012; 25(1):38-44. PubMed ID: 22458048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of the ubiquitin proteasome system in lymphoma.
    Suh KS; Tanaka T; Sarojini S; Nightingale G; Gharbaran R; Pecora A; Goy A
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):306-22. PubMed ID: 23541070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
    Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
    Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
    Johnson DE
    Endocr Relat Cancer; 2015 Feb; 22(1):T1-17. PubMed ID: 24659480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of 19S proteasome associated deubiquitinases in activity-dependent hippocampal synaptic plasticity.
    Yun D; Zhuang Y; Kreutz MR; Behnisch T
    Neuropharmacology; 2018 May; 133():354-365. PubMed ID: 29407217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Proteasomal Deubiquitinase by Silver Complex Induces Apoptosis in Non-Small Cell Lung Cancer Cells.
    Chen X; Yang Q; Chen J; Zhang P; Huang Q; Zhang X; Yang L; Xu D; Zhao C; Wang X; Liu J
    Cell Physiol Biochem; 2018; 49(2):780-797. PubMed ID: 30165348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteasome inhibitors in cancer therapy: lessons from the first decade.
    Orlowski RZ; Kuhn DJ
    Clin Cancer Res; 2008 Mar; 14(6):1649-57. PubMed ID: 18347166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.
    Jiang L; Sun Y; Wang J; He Q; Chen X; Lan X; Chen J; Dou QP; Shi X; Liu J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):453. PubMed ID: 31694672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
    Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
    Driscoll JJ; Dechowdhury R
    Target Oncol; 2010 Dec; 5(4):281-9. PubMed ID: 21125340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deubiquitinase inhibition as a cancer therapeutic strategy.
    D'Arcy P; Wang X; Linder S
    Pharmacol Ther; 2015 Mar; 147():32-54. PubMed ID: 25444757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasome inhibition as a novel therapeutic target in human cancer.
    Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
    J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Covalent and non-covalent reversible proteasome inhibition.
    Beck P; Dubiella C; Groll M
    Biol Chem; 2012 Oct; 393(10):1101-20. PubMed ID: 23091276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-Driven Developments of 26S Proteasome Inhibitors.
    Śledź P; Baumeister W
    Annu Rev Pharmacol Toxicol; 2016; 56():191-209. PubMed ID: 26738474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers.
    Cai J; Xia X; Liao Y; Liu N; Guo Z; Chen J; Yang L; Long H; Yang Q; Zhang X; Xiao L; Wang X; Huang H; Liu J
    Oncotarget; 2017 Sep; 8(38):63232-63246. PubMed ID: 28968984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.